Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY 59-7939 versus enoxaparin after elective total hip replacement
ACTRN12606000068561Phase 3Completed
- Sponsor
- Bayer
- Start
- Apr 2006
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in venous thromboembolism (VTE) comparing rivaroxaban arm with enoxaparin arm (2 arms). Primary endpoints: Primary efficacy endpoint: any deep vein thrombosis, Primary efficacy endpoint: non-fatal pulmonary embolism and 1 more. Started Apr 2006; status: completed.
02
Drugs
rivaroxabanenoxaparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on ACTRN12606000068561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12606000068561.